Market Fallers: Anglo American, Antofagasta, AstraZeneca, Berkeley Group

Antofagasta Plc
[shareaholic app="share_buttons" id_name="post_below_content"]

The stock price for Anglo American found using EPIC: LON:AAL has dropped -1.63% or -32.6 points during today’s session so far. Investors were far from a positive bunch throughout the trading session. The periods high has already touched 2003.5 while the low for the session was 1950. Volume total for shares traded at this point reached 1,085,980 with the daily average number around 6,004,810. The 52 week high for the share price is 2294 some 296 points in difference to the previous days close of business and a 52 week low sitting at 1529.8 making a difference of 468.2 points. Anglo American has a 20 SMA of 1942.24 and now a 50 day moving average now at 1889.02. The market cap now stands at £27,043.65m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Anglo American being recorded at Thursday, October 31, 2019 at 12:04:46 PM GMT with the stock price trading at 1965.4 GBX.

Shares of Antofagasta ticker lookup code: LON:ANTO has moved down -2.11% or -18.6 points throughout the session so far. Traders were not positive during the trading session. The high for the period has reached 885 and hitting a low of 851.4. The number of shares traded by this point in time totalled 388,426 with the daily average traded share volume around 2,254,436. A 52 week high for the stock is 1026 some 144.2 points in difference on the previous days close and a 52 week low being 727.6 is a variance of 154.2 points. Antofagasta has a 20 day moving average of 875.04 and a 50 day MA at 886.04. The market capitalisation currently stands at £8,498.09m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for Antofagasta being recorded at Thursday, October 31, 2019 at 12:04:39 PM GMT with the stock price trading at 863.2 GBX.

Shares of AstraZeneca ticker lookup code: LON:AZN has stepped down -1.79% or -136 points in today’s trading session so far. Investors have so far given a mostly negative outlook during the session. The periods high has reached 7646 dropping as low as 7440. The total volume of shares traded by this point was 547,821 whilst the average number of shares exchanged is 2,348,768. The 52 week high price for the shares is 7646 some 66 points difference from the previous days close and the 52 week low at 5312 making a difference of 2268 points. AstraZeneca has a 20 day moving average of 7147.88 and the 50 day moving average at 7216.31. The market cap now stands at £97,657.42m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Thursday, October 31, 2019 at 12:04:19 PM GMT with the stock price trading at 7444 GBX.

Stock in Berkeley Group with ticker code: LON:BKG has decreased -1.72% or -77 points throughout today’s trading session so far. Sellers were not positive during the trading session. The periods high has reached 4424 dropping as low as 4329. Volume total for shares traded during this period was 148,234 whilst the average number of shares exchanged is 577,984. The stock 52 week high is 4622 which is 157 points difference from the previous close and the 52 week low at 3170 which is a difference of 1295 points. Berkeley Group Holdings has a 20 SMA of 4360.03 and now the 50 day simple moving average now at 4189.37. This puts the market cap at £5,523.84m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Berkeley Group Holdings being recorded at Thursday, October 31, 2019 at 12:04:37 PM GMT with the stock price trading at 4388 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Berkeley Group Holdings reports a strong pre-tax profit of £275 million for the first half of 2024, despite challenging market conditions.
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.

      Search

      Search